2022-11-242022-11-242020-09-30Cevhertaş, L. vd. (2020). "Advances and recent developments in asthma in 2020". Allergy: European Journal of Allergy and Clinical Immunology, 75(12), 3124-3146.0105-4538https://onlinelibrary.wiley.com/doi/full/10.1111/all.14607https://doi.org/10.1111/all.14607http://hdl.handle.net/11452/29554Bu çalışmada 22 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.In this review, we discuss recent publications on asthma and review the studies that have reported on the different aspects of the prevalence, risk factors and prevention, mechanisms, diagnosis, and treatment of asthma. Many risk and protective factors and molecular mechanisms are involved in the development of asthma. Emerging concepts and challenges in implementing the exposome paradigm and its application in allergic diseases and asthma are reviewed, including genetic and epigenetic factors, microbial dysbiosis, and environmental exposure, particularly to indoor and outdoor substances. The most relevant experimental studies further advancing the understanding of molecular and immune mechanisms with potential new targets for the development of therapeutics are discussed. A reliable diagnosis of asthma, disease endotyping, and monitoring its severity are of great importance in the management of asthma. Correct evaluation and management of asthma comorbidity/multimorbidity, including interaction with asthma phenotypes and its value for the precision medicine approach and validation of predictive biomarkers, are further detailed. Novel approaches and strategies in asthma treatment linked to mechanisms and endotypes of asthma, particularly biologicals, are critically appraised. Finally, due to the recent pandemics and its impact on patient management, we discuss the challenges, relationships, and molecular mechanisms between asthma, allergies, SARS-CoV-2, and COVID-19.eninfo:eu-repo/semantics/openAccessAsthma biomarkersAsthma phenotypesBiological therapeuticsComorbiditiesCovid-19Allergen immunotherapyArginase inhibitorsBlood eosinophilsEeeaci guidelinesFood allergyRhinitsManagementOmalizumabPathologyParadigmAllergyImmunologyAsthmaBiomarkersComorbidityCovid-19DysbiosisExposomeHumansPandemicsPhenotypePrecision medicineRisk factorsArticle0005776230000012-s2.0-8509259337931243146751232997808AllergyImmunologyBenralizumab; Asthma; Fractional Exhaled Nitric OxideBiological markerProteinBiological markerAdultAllergic diseaseAsthmaChildComorbidityCoronavirus disease 2019Dietary supplementDisease severityDysbiosisEnvironmentEnvironmental exposureEpigeneticsExposomeHeredityHumanNonhumanObesityPandemicPersonalized medicinePhenotypePrevalencePriority journalReviewRisk factorSevere acute respiratory syndrome coronavirus 2Sex differenceSignal transductionSmokingAsthmaHypersensitivity